Newer targeted drugs worked better than standard treatment for HER2-positive breast cancer
Original title: Efficacy evaluation of novel targeted drugs in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis based on multiple sets of clinical data.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
These drugs have already been tested in people in trials, and this is a summary of those results.
The short version
A review of past trials found that newer HER2 drugs helped people live longer and caused fewer side effects than older treatment.
What was studied. Researchers pooled results from earlier studies of adult women with HER2-positive breast cancer. The women were treated with newer drugs such as T-DXd, margetuximab, and tucatinib, and their results were compared with standard treatment.
What they found. Eight studies were included, chosen from 2567 records the team searched. People on the newer drugs lived longer, and it took longer for their cancer to grow. Tumors shrank in 50% of people on the newer drugs, compared with 35% on standard treatment, and the cancer stayed under control in 80% compared with 60%. Heart problems happened in 5% of people on the newer drugs, compared with 15% on standard treatment. Stomach and bowel problems happened in 10%, compared with 25%.
What this means, and what it doesn't
What it could mean: If you have HER2-positive breast cancer, there may be newer drug options that work better than older ones. The review found the benefit looked larger in two groups. One was people whose cancer was hormone receptor negative. The other was people whose cancer had spread to the brain. Your own doctor can tell you if any of these drugs fit your case.
What it doesn't mean: This is not a new treatment and it is not a cure. It is a review that gathers up results from studies that were already done, and only eight studies were included. It is also about breast cancer, including cancer that spread to the brain, not about tumors that start in the brain. Results in a pooled review are an average. They do not tell you what will happen for one person. Side effects still happen with these drugs, just less often in this review.
Source: PubMed, July 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.